Skip to content

Bio-Rad Laboratories

US · BIO #1479 by market cap Listed 1970
358.90 -8.60 -2.34%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $90
    Market Newswire · 2026/11/13
  • Bio-Rad Laboratories | 8-K: Bio-Rad Reports Third -Quarter 2026 Financial Results
    SEC · 2026/11/5
  • Company notice
    Weiguang Bio: Legal Opinion of King & Wood Mallesons (Shenzhen) on the Second Extraordinary Shareholders' Meeting of Shenzhen Weiguang Biological Products Co., Ltd. for 2026
    SZSI · 2026/11/14
  • Company notice
    Zhijiang Bio: Legal Opinion of Zhejiang TianCe Law Firm Regarding the Second Extraordinary Shareholders' Meeting of Shanghai Zhijiang Biotechnology Co., Ltd. for 2026
    SZSI · 2026/11/14
  • Company notice
    ADAPTIN BIO INC. | 10-Q: Quarterly report
    SEC · 2026/11/14
  • Rating change
    Freedom Capital Markets Initiates INmune Bio(INMB.US) With Buy Rating, Announces Target Price $2.5
    Market Newswire · 2026/11/13
  • RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $440
    Market Newswire · 2026/11/5
  • Rating change
    Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/11/13
  • Company notice
    Bio-Thera Solutions: Legal Opinion of Fangda (Guangzhou) Law Firm, Shanghai, Regarding the Third Extraordinary Shareholders' Meeting of Bio-Thera Solutions Ltd. in 2026
    SZSI · 2026/11/14
  • Rating change
    CCORF Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $2
    Market Newswire · 2026/11/12
  • Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B Vs $2.588B Est
    Benzinga · 2026/11/5
  • Bio-Rad Laboratories | 10-Q: Q3 2026 Earnings Report
    SEC · 2026/11/5
  • Company notice
    Kechian Bio: Announcement by Wuhan Kechian Bio Co., Ltd. Regarding the Convening of the Third-Quarter 2026 Earnings Conference Call
    SZSI · 2026/11/14
  • Rating change
    Goldman Sachs Maintains Braveheart Bio(BRVE.US) With Buy Rating, Raises Target Price to $49
    Market Newswire · 2026/11/12
  • Bio-Rad Laboratories Q3 Adj. EPS $2.65 Beats $2.23 Estimate, Sales $656.400M Beat $649.950M Estimate
    Benzinga · 2026/11/5
  • Rating change
    Piper Sandler Maintains TELA Bio(TELA.US) With Hold Rating, Maintains Target Price $1
    Market Newswire · 2026/11/11
  • Rating change
    Leerink Partners Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $215
    Market Newswire · 2026/11/13
  • Rating change
    H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245
    Market Newswire · 2026/11/13
  • Rating change
    B. Riley Securities Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7
    Market Newswire · 2026/11/13
  • Rating change
    Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/11/12
  • Rating change
    Argus Research Downgrades Bio-Techne(TECH.US) to Sell Rating
    Market Newswire · 2026/10/27
  • Rating change
    Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/10/30
  • Rating change
    H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7
    Market Newswire · 2026/10/29
  • Rating change
    Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/10/27
  • Rating change
    Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/10/26

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Bio-Rad Laboratories discussion 0 comments

Add a comment